Forte Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2015
Net Income	-32.14	-31.48	-13.88	-21.71	-46.49	-4.07	Upgrade
Depreciation & Amortization	0.02	0.01	0	0.04	0.05	0.01	Upgrade
Share-Based Compensation	3.21	3.28	4.02	4.21	0.96	0.04	Upgrade
Other Operating Activities	-1.26	-0.52	1.68	0.78	27.05	1.25	Upgrade
Operating Cash Flow	-30.17	-28.71	-8.19	-16.68	-18.42	-2.77	Upgrade
Capital Expenditures	-0.09	-0.09	0	0	0	-0.16	Upgrade
Acquisitions	0	0	0	0	3.58	0	Upgrade
Change in Investments	10.1	0.14	0	0	0	0	Upgrade
Investing Cash Flow	10.01	0.05	0	0	3.58	-0.16	Upgrade
Share Issuance / Repurchase	24.75	24.74	7.24	0.06	66.96	0	Upgrade
Other Financing Activities	-0.08	-0.06	-	-0.11	-0.29	4.86	Upgrade
Financing Cash Flow	24.67	24.68	7.24	-0.04	66.67	4.86	Upgrade
Net Cash Flow	-5.46	-3.98	-0.94	-16.72	51.83	1.92	Upgrade
Free Cash Flow	-30.26	-28.79	-8.19	-16.68	-18.42	-2.93	Upgrade
Free Cash Flow Per Share	-0.66	-0.91	-0.47	-1.19	-2.50	-1.39	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).